Neuro-Oncology Branch: Clinical Trials
-
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0015Investigator Mark R. Gilbert, M.D. -
A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms
Open - RecruitingNCI Protocol ID NCI-20-C-0069Investigator Mark R. Gilbert, M.D. -
A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
Open - RecruitingNCI Protocol ID NCI-20-C-0065Investigator Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANPShare this trial: Referral ContactsContact Name Phone Number NCINOBReferrals@mail.nih.gov 240-760-6010 -
Studying the biology of IDH-mutant gliomas via longitudinal observation of 2-hydroxyglutarate (2-HG) using MR spectroscopy
Open - RecruitingNCI Protocol ID NCI-19-C-0096Investigator Jing Wu, M.D., Ph.D. -
Phase II trial evaluating Nivolumab in patients with IDH-mutant gliomas with and without hypermutator phenotype
Open - RecruitingNCI Protocol ID NCI-19-C-0006Investigator Jing Wu, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Kathleen Wall 240.760.7236 Kelly Mentges 240.760.7126 -
Exploring Outcomes and Risk in Patients with Rare Central Nervous System Tumors
Open - RecruitingNCI Protocol ID 17-C-N141Investigator Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP -
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Open - RecruitingNCI Protocol ID NCI-17-C-0102Investigator Marta Penas-Prado, M.D.Share this trial: Referral ContactsContact Name Phone Number Kathleen Wall 240.760.7236 Ukeme Ikiddeh-Barnes 240.858.7083 -
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Open - RecruitingNCI Protocol ID NCI-17-C-0037Investigator Eric C. Burton, M.D. -
A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM)
Open - RecruitingNCI Protocol ID NCI-17-C-0034Investigator Mark R. Gilbert, M.D.Share this trial: Referral ContactsContact Name Phone Number Matthew Lindsley 240.760.6534 Ukeme Ikiddeh-Barnes 240.858.7083 -
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
Open - RecruitingNCI Protocol ID NCI-16-C-0151Investigator Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP